S. 2328 · 108th Congress
Imports of Prescription Drugs bill
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 108th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
DorganSponsor31 cosponsors · 25 D, 5 R, 1 I
R
Chafee
TD
D
Daschle
RF
D
Feingold
TJ
D
Johnson
TK
D
Kennedy
TL
R
Lott
JM
R
McCain
MP
D
Pryor
OS
R
Snowe
DS
D
Stabenow
MD
D
Dayton
DF
D
Feinstein
BN
D
Nelson
CS
D
Schumer
JK
D
Kerry
PL
D
Leahy
BB
D
Boxer
RD
D
Durbin
BM
D
Mikulski
CL
D
Levin
HK
D
Kohl
DI
D
Inouye
HC
D
Clinton
BL
D
Lincoln
AS
R
Specter
JJ
I
Jeffords
JE
D
Edwards
KC
D
Conrad
HR
D
Reid
PS
D
Sarbanes
CD
D
Dodd10 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Pharmaceutical Market Access and Drug Safety Act of 2004 - Amends the Federal Food, Drug, and Cosmetic Act to revise provisions governing the importation of prescription drugs.
What it does: CRS summary · Introduced in Senate · Apr 21, 2004
Pharmaceutical Market Access and Drug Safety Act of 2004 - Amends the Federal Food, Drug, and Cosmetic Act to revise provisions governing the importation of prescription drugs. Requires the Secretary of Health and Human Services to promulgate regulations allowing the importation of prescription drugs by registered exporters or registered importers from Canada within 90 days of passage of this Act and from Australia, European Union countries, Japan, New Zealand, or Switzerland within one year.
Provides for inspection, tracking of drugs, and registration and inspection fees for registered importers and exporters.
Requires manufacturers to: (1) submit a statement to the Secretary explaining each difference between a drug approved and distributed in the United States and a related drug distributed in a foreign country; and (2) submit an application to the Food and Drug Administration (FDA) for approval of a related drug that is distributed in a foreign country if there is no comparable drug already approved in at least half of the permitted countries that can be imported to the United States.
Allows for the immediate importation of prescription drugs for personal use from licensed Canadian pharmacies.
Amends the Clayton Act to prohibit drug manufacturers from preventing importation by engaging in behavior such as charging higher prices or limiting supplies to registered exporters and importers or changing the form of the drug for such purpose.
States that the resale in the United States of prescription drugs that were properly sold abroad is not patent infringement.
Requires the Secretary of Homeland Security to refuse admission of drugs that violate importation provisions. Allows the destruction of certain violative shipments.
Amends the Controlled Substances Act to repeal the exemption that permitted individuals to import controlled substances for personal medical use.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Pharmaceutical Market Access and Drug Safety Act of 2004
Latest action (Jul 14, 2004): Committee on the Judiciary. Hearings held.
Policy area: Health · Origin: Senate · Introduced: Apr 21, 2004
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML) · Embed in your story
No recorded floor vote found.